NT5E and lung carcinoma: A new study in pancreatic ductal adenocarcinoma (PDAC), where almost 80% of cases are KRAS mutant, demonstrated that activating mutation in KRAS alone is sufficient to elevate levels of CD73 suggesting that CD73 induction with oncogenes extends beyond lung cancer (78).